OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals
Ana M. López-Estévez, Philipp Lapuhs, Laura Pineiro‐Alonso, et al.
Advanced Materials (2023) Vol. 36, Iss. 14
Open Access | Times Cited: 20
Ana M. López-Estévez, Philipp Lapuhs, Laura Pineiro‐Alonso, et al.
Advanced Materials (2023) Vol. 36, Iss. 14
Open Access | Times Cited: 20
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun‐Hao Pan, et al.
Cancer Discovery (2023) Vol. 14, Iss. 2, pp. 308-325
Open Access | Times Cited: 19
Zhuxuan Li, Xueqian Zhuang, Chun‐Hao Pan, et al.
Cancer Discovery (2023) Vol. 14, Iss. 2, pp. 308-325
Open Access | Times Cited: 19
STAT3 Sustains Tumorigenicity Following Mutant KRAS Ablation
Stephen D’Amico, Varvara Kirillov, Jingxuan Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Stephen D’Amico, Varvara Kirillov, Jingxuan Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Mesenchymal Stem Cell-Derived Exosomes in Cancer Resistance Against Therapeutics
Vignesh Balaji E, Keerthilatha M. Pai, K. Sreedhara Ranganath Pai
Cancers (2025) Vol. 17, Iss. 5, pp. 831-831
Open Access
Vignesh Balaji E, Keerthilatha M. Pai, K. Sreedhara Ranganath Pai
Cancers (2025) Vol. 17, Iss. 5, pp. 831-831
Open Access
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Charles Parry, Francesca Pellicano, Alexander W. Schüttelkopf, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Charles Parry, Francesca Pellicano, Alexander W. Schüttelkopf, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Irati Macaya, Marta Román, Connor Welch, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Irati Macaya, Marta Román, Connor Welch, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS mutations
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
Aoife A. Nolan, Cinzia Raso, Walter Kölch, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4141-4141
Open Access | Times Cited: 7
Aoife A. Nolan, Cinzia Raso, Walter Kölch, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4141-4141
Open Access | Times Cited: 7
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
Rafael Rosell, Carlos Pedraz‐Valdunciel, Anisha Jain, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 171-182
Closed Access | Times Cited: 2
Rafael Rosell, Carlos Pedraz‐Valdunciel, Anisha Jain, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 171-182
Closed Access | Times Cited: 2
Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors
Ana M. López-Estévez, Lucía Sanjurjo, Ángela Turrero, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 277-292
Open Access | Times Cited: 2
Ana M. López-Estévez, Lucía Sanjurjo, Ángela Turrero, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 277-292
Open Access | Times Cited: 2
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 12, pp. 1422-1433
Open Access | Times Cited: 5
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 12, pp. 1422-1433
Open Access | Times Cited: 5
Oncogenic dependency plays a dominant role in the immune response to cancer
Jinyu Li, Stephen D’Amico, Varvara Kirillov, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 41
Open Access | Times Cited: 5
Jinyu Li, Stephen D’Amico, Varvara Kirillov, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 41
Open Access | Times Cited: 5
Natural Product Graveoline Modulates Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Membrane Association: Insights from Advanced Spectroscopic Studies
Gabriel Cornilescu, Lakshman Bindu, Louise M. Sternicki, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 7, pp. 1983-1995
Closed Access | Times Cited: 1
Gabriel Cornilescu, Lakshman Bindu, Louise M. Sternicki, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 7, pp. 1983-1995
Closed Access | Times Cited: 1
Increased dosage of wild-type KRAS protein drivesKRAS-mutant lung tumorigenesis and drug resistance
Tonči Ivanišević, Wout Magits, Yan Ma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Tonči Ivanišević, Wout Magits, Yan Ma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Association of 3'UTR variations of EGFR and KRAS oncogenes with clinical parameters in lung cancer tumours
Özkan Bağcı
Biology of the Cell (2024)
Closed Access | Times Cited: 1
Özkan Bağcı
Biology of the Cell (2024)
Closed Access | Times Cited: 1
Association of KRAS Gene and microRNA-124-3p in Sporadic Colorectal Tumours
Özkan Bağcı
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 01, pp. 150-161
Open Access
Özkan Bağcı
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 01, pp. 150-161
Open Access
Peptidoform analysis of IP-MS data allows detection of differentially present bait proteoforms
Sara Sdelci, Sara Sdelci, Savvas Kourtis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Sara Sdelci, Sara Sdelci, Savvas Kourtis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Detection of differential bait proteoforms through immunoprecipitation-mass spectrometry data analysis
Savvas Kourtis, Damiano Cianferoni, Luís Serrano, et al.
Scientific Data (2024) Vol. 11, Iss. 1
Open Access
Savvas Kourtis, Damiano Cianferoni, Luís Serrano, et al.
Scientific Data (2024) Vol. 11, Iss. 1
Open Access
KRAS combination strategies: How well aligned is clinical and preclinical research?
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
